Natco Pharma: revenue rises quarter on quarter but falls year on year on lenalidomide
Natco Pharma's second-quarter FY27 revenue grew sequentially on international formulation sales but declined annually as lenalidomide income dropped.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Natco Pharma's revenue in the second quarter of fiscal 2027 increased from the previous quarter, supported by stronger sales of formulations in international markets. Compared with a year earlier, however, revenue fell because lenalidomide sales were lower.
Consolidated profit after tax came to ₹202.6 crore. Adcock Ingram's stake in the company rose to 49%, and the company declared an interim dividend of ₹1.25.
The details come from TradingView, which cites the original document and notes that the summary was generated with AI and may contain inaccuracies.
why it matters
For investors the story matters mainly as an update on one Indian drugmaker: dependence on a few products remains a visible factor in its revenue, and Adcock Ingram's higher stake changes the company's ownership structure.
tags
instruments
sources
- NATCOPHARM: QoQ recovery in international formulations could not offset lower Lenalidomide revenue YoY — TradingView, 13 November 2026 at 08:47 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗